Neurogene Inc. Stock Price

NasdaqGM:NGNE Community·US$704.2m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
6 Fair Values set on narratives written by author

Author Program NEW Create Narrative

NGNE Share Price Performance

US$32.56

13.06 (66.97%)

US$32.56

13.06 (66.97%)

US$32.56

Tue, 7 Jul 26

Share Pricen/a

NGNE Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Excellent balance sheet and good value.

3 Risks

1 Reward

View Full Analysis

Neurogene Inc. Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: -4.95
: 0%
: 0%
: 0%

View Full Analysis

About NGNE

Founded: 2018
Employees: 131
CEO: Rachel McMinn
WebsiteView website: www.neurogene.com

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.